Tissue Factor Targeted Near-Infrared Photoimmunotherapy for Cancer Treatment
Author Information
Author(s): Takao Seiichiro, Fukushima Hiroshi, Furusawa Aki, Kato Takuya, Okuyama Shuhei, Kano Makoto, Yamamoto Hiroshi, Suzuki Motofumi, Kano Miyu, Choyke Peter L., Kobayashi Hisataka
Primary Institution: National Cancer Institute, NIH
Hypothesis
Can tissue factor-targeted near-infrared photoimmunotherapy (NIR-PIT) effectively treat various types of cancer?
Conclusion
TF-targeted NIR-PIT shows promise as an effective treatment for multiple cancer types expressing tissue factor.
Supporting Evidence
- TF-targeted NIR-PIT caused cell death in a light dose-dependent manner.
- TF expression was documented to localize to cancer cells in tumors.
- In vivo, TF-targeted NIR-PIT suppressed tumor growth and improved survival rates compared to controls.
- Histological signs of cancer cell damage were observed after NIR-PIT.
- TF is commonly expressed in pancreatic cancer, making it a viable therapeutic target.
Takeaway
This study shows that a special light therapy targeting a protein found in many cancers can help kill cancer cells and make patients live longer.
Methodology
The study involved in vitro and in vivo experiments using cancer cell lines and mouse models to evaluate the efficacy of TF-targeted NIR-PIT.
Potential Biases
Potential bias due to the use of specific cancer cell lines and animal models.
Limitations
The study used human cell line-derived xenografts in immunodeficient mice, limiting the assessment of immune activation effects.
Participant Demographics
{"age":{"median":56,"range":"23-80"},"gender":{"female":27,"male":41},"clinical_stage":{"IA":2,"IB":24,"IIA":28,"IIB":12,"III":0,"IV":2}}
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website